Abstract:Importance: Small cell lung cancer (SCLC) is an aggressive disease that is characterized by rapid growth and the early development of metastases. Patients typically respond to initial chemotherapy but quickly experience relapse, resulting in a poor long-term outcome. Therapeutic innovations that substantially improve survival have historically been limited, and reliable, predictive biomarkers are lacking. Observations: This review examines the biologic characteristics of SCLC, the current treatment landscape, and ongoing efforts to identify novel therapeutic targets. Ongoing research has advanced the understanding of molecular categories and the immunologic microenvironment of SCLC, which in turn has helped improve disease classification and staging. Recently, immunotherapy-based regimens have become available for the management of SCLC, with 2 programmed cell death 1 ligand 1 inhibitors approved in combination with chemotherapy for first-line treatment of extensive-stage disease. For second-line treatment, a novel alkylating agent, lurbinectedin, which inhibits oncogenic transcription, has been approved for use in patients with metastatic SCLC. Furthermore, a wide variety of therapies and innovative combination regimens are being continuously evaluated. Potential therapeutic strategies, including aurora kinase A inhibitors, polyadenosine diphosphate-ribose polymerase inhibitors, ataxia telangiectasia and Rad3-related inhibitors, cyclin-dependent kinase 7 inhibitors, delta-like protein 3 agents, antiganglioside agents, CD47 inhibitors, and lysine-specific histone demethylase 1a inhibitors, are also being examined. Conclusions and relevance: Therapeutic optimization of SCLC remains a challenge, but recent trial results and drug approvals are encouraging. Advances in research have revealed critical information regarding biologic characteristics of the disease, which may lead to the identification of vulnerabilities and the development of new therapies. Further research focused on identifying biomarkers and evaluating innovative therapies will be paramount to improving treatment outcomes for patients with SCLC.

New insights into small‐cell lung cancer development and therapy

Opportunities and obstacles of targeted therapy and immunotherapy in small cell lung cancer

[Recent Advances and Future Strategies for Small Cell Lung Cancer].

Current Small Cell Lung Cancer Treatment In China

Immunotherapy for small cell lung cancer: the current state and future trajectories

Research progress in the treatment of small cell lung cancer

Emerging Strategies for the Treatment of Small Cell Lung Cancer: A Review

Current Diagnosis and Management of Small-Cell Lung Cancer

Small Cell Lung Cancer—An Update on Chemotherapy Resistance

Update 2021: Management of Small Cell Lung Cancer

The research advances of drug therapy of small cell lung cancer

Accurate treatment of small cell lung cancer: Current progress, new challenges and expectations

Current Status and Progress of the Treatment of Limited-Disease Small Cell Lung Cancer

Recent developments in the treatment of small cell lung cancer

Small cell lung cancer: emerging subtypes, signaling pathways, and therapeutic vulnerabilities

Small cells – big issues: biological implications and preclinical advancements in small cell lung cancer

Advances in novel molecular typing and precise treatment strategies for small cell lung cancer

Small Cell Lung Cancer: Will Recent Progress Lead to Improved Outcomes?

A New Hope: the Immunotherapy in Small Cell Lung Cancer

Progress in the clinical application of immune checkpoint inhibitors in small cell lung cancer

Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions